Saturday, October 25, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Analysts Identify Significant Upside Potential in Asure Software Shares

Andreas Sommer by Andreas Sommer
September 6, 2025
in Analysis, Tech & Software, Turnaround
0
Asure Software Stock
0
SHARES
134
VIEWS
Share on FacebookShare on Twitter

Despite presenting a mixed financial picture, Asure Software is capturing significant analyst optimism for its future trajectory. The cloud-based human capital management specialist is experiencing a notable sentiment shift, driven not by current performance but by substantial growth expectations. Market experts highlight a considerable gap between the stock’s present valuation and their projected price targets.

The recent strategic acquisition of Lathem Time Corporation appears to be a pivotal move. Management used their July quarterly presentation to substantially upgrade their annual guidance, raising it from the previous $134-138 million range to $138-142 million. This confident forecast revision, coming immediately after finalizing the acquisition, overshadowed disappointing Q2 results and propelled the stock upward by 8% in after-hours trading following the announcement.

This optimism is reflected in concrete analyst actions. Multiple firms reaffirmed their buy recommendations on Friday, with several establishing price targets reaching as high as $15. This represents potential appreciation of nearly 70% from current trading levels. Even more conservative estimates remain significantly above $13, suggesting widespread belief that the market is undervaluing Asure’s long-term growth narrative.

Should investors sell immediately? Or is it worth buying Asure Software?

Institutional investors are demonstrating substantial confidence through increased positions. During the last quarter, these major market participants boosted their ownership in Asure by over 36%, now controlling more than 70% of outstanding shares. This strong institutional backing, maintained despite current GAAP losses, indicates deep conviction in the company’s turnaround strategy. Management anticipates achieving GAAP profitability by the fourth quarter of 2025.

The coming weeks present critical opportunities for Asure to validate this optimism. Company leadership is scheduled to participate in two investor conferences in mid-September, providing platforms to elaborate on their strategic vision and reinforce market confidence. For investors who believe in the cloud HCM growth story, Asure represents one of the market’s most compelling opportunities.

Ad

Asure Software Stock: Buy or Sell?! New Asure Software Analysis from October 24 delivers the answer:

The latest Asure Software figures speak for themselves: Urgent action needed for Asure Software investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 24.

Asure Software: Buy or sell? Read more here...

Tags: Asure Software
Andreas Sommer

Andreas Sommer

About Andreas Sommer Over 40 years of expertise in market analysis, chart technical analysis, and strategic investment advisory. With more than four decades of experience in banking and financial journalism, Andreas Sommer is recognized as one of the leading analysts in the German-speaking market. His deep understanding of market dynamics and technical analysis has helped countless investors navigate complex financial markets.
Areas of Expertise:
  • Technical Chart Analysis
  • Strategic Investment Advisory
  • Market Trend Analysis
  • Financial Journalism
Andreas brings unparalleled insights from his extensive career in banking and financial markets, making him a trusted voice for investors seeking professional guidance.

Related Posts

BASF Stock
Analysis

A Tale of Two Titans: Comparing Investment Strategies in Germany’s Chemical Sector

October 24, 2025
Puma Stock
Analysis

Can Puma’s Radical Overhaul Reverse Its Downward Spiral?

October 24, 2025
Cellectar Biosciences Stock
Analysis

Cellectar Biosciences at a Critical Juncture: Regulatory and Financial Developments Converge

October 24, 2025
Next Post
Big 5 Sporting Goods Stock

Shareholders to Decide Fate of Big 5 Sporting Goods Acquisition

Robinhood Stock

Robinhood's S&P 500 Inclusion: A Watershed Moment for Fintech

Boyd Gaming Stock

Strategic Divestiture Fuels Boyd Gaming's Financial Transformation

Recommended

Allied Motion Stock

Allied Motion Posts Record Profit Margins and Soaring Earnings

2 months ago
Biotechnology Stock Exchange

Analysts Bullish on Alpine Immune Sciences Price Targets and Ratings Upgraded

2 years ago
AutoZone Stock

AutoZone Earnings Preview: High Expectations Set the Stage

1 month ago
Finance_ Chart Down

Analyst Adjusts Price Target for MVB Financial Diverse Opinions in the Financial Industry

2 years ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BioNTech Broadcom Coinbase Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Nike NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power QuantumScape Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Can Puma’s Radical Overhaul Reverse Its Downward Spiral?

Bitcoin’s Calm Consolidation Masks Significant Accumulation

Cellectar Biosciences at a Critical Juncture: Regulatory and Financial Developments Converge

Super Micro Stock Plummets After Stunning Forecast Downgrade

3M Shares Surge on Strong Quarterly Performance and Upbeat Forecast

High-Yield Gamble: The Oxford Square Capital Investment Dilemma

Trending

BASF Stock
Analysis

A Tale of Two Titans: Comparing Investment Strategies in Germany’s Chemical Sector

by Dieter Jaworski
October 24, 2025
0

Within Germany's prestigious chemical industry, two distinct competitors present investors with fundamentally different value propositions. On one...

Novo Nordisk Stock

Leadership Shakeup at Novo Nordisk Sparks Investor Uncertainty

October 24, 2025
CureVac Stock

CureVac Acquisition Enters Final Phase as BioNTech Makes Formal Bid

October 24, 2025
Puma Stock

Can Puma’s Radical Overhaul Reverse Its Downward Spiral?

October 24, 2025
Bitcoin Stock

Bitcoin’s Calm Consolidation Masks Significant Accumulation

October 24, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • A Tale of Two Titans: Comparing Investment Strategies in Germany’s Chemical Sector
  • Leadership Shakeup at Novo Nordisk Sparks Investor Uncertainty
  • CureVac Acquisition Enters Final Phase as BioNTech Makes Formal Bid

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com